Proteasome activation is a mechanism for pyrazolone small molecules displaying therapeutic potential in amyotrophic lateral sclerosis

ACS Chemical Neuroscience

Volumn 5, Issue 9, 2014, Pages 823-829

  Trippier, Paul C ^a,d,e   Zhao, Kevin Tianmeng ^a   Fox, Susan G ^b   Schiefer, Isaac T ^a   Benmohamed, Radhia ^c   Moran, Jason ^a   Kirsch, Donald R ^c   Morimoto, Richard I ^a   Silverman, Richard B ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Center for Molecular Innovation and Drug Discovery   (United States)

^c Cambria Pharmaceuticals   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e TEXAS TECH UNIVERSITY   (United States)

Author keywords

Amyotrophic lateral sclerosis; Drug discovery; Neurodegeneration; Proteasome activator; Pyrazolone; Target identification

Indexed keywords

26S PROTEASOME REGULATORY SUBUNIT 4; 26S PROTEASOME REGULATORY SUBUNIT 6B; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CHAPERONIN CONTAINING TCP1; NEUROPROTECTIVE AGENT; PROTEASOME; PROTEASOME INHIBITOR; PYRAZOLONE DERIVATIVE; UNCLASSIFIED DRUG; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CELL CYCLE PROTEIN; CYSTEINE PROTEINASE INHIBITOR; LEUPEPTIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOTOPROTEIN; PYRAZOLONE; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE; UBIQUITIN; UBQLN2 PROTEIN, HUMAN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; CELL LYSATE; CONTROLLED STUDY; EC50; HEAT SHOCK RESPONSE; HELA CELL LINE; NEUROPROTECTION; NONHUMAN; PC12 CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; PROTEOMICS; RAT; ANIMAL; BIOTINYLATION; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; HEAT; HUMAN; METABOLISM; TANDEM MASS SPECTROMETRY;

MURINAE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOTINYLATION; CELL CYCLE PROTEINS; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HOT TEMPERATURE; HUMANS; LEUPEPTINS; LUMINESCENT PROTEINS; MODELS, MOLECULAR; PC12 CELLS; PROTEOMICS; PYRAZOLONES; RATS; SUPEROXIDE DISMUTASE; TANDEM MASS SPECTROMETRY; UBIQUITINS;

EID: 84924980848     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn500147v     Document Type: Article

References (38)

1. Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., Ohama, E., Reaume, A. G., Scott, R. W., and Cleveland, D. W. (1998) Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851-1854.
2. Pasinelli, P., and Brown, R. H. (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci. 7, 710-723.
3. Haidet-Phillips, A. M., Hester, M. E., Miranda, C. J., Meyer, K., Braun, L., Frakes, A., Song, S., Likhite, S., Murtha, M. J., Foust, K. D., Rao, M., Eagle, A., Kammesheidt, A., Christensen, A., Mendell, J. R., Burghes, A. H., and Kaspar, B. K. (2011) Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 29, 824-828.
4. Gagliardi, S., Cova, E., Davin, A., Guareschi, S., Abel, K., Alvisi, E., Laforenza, U., Ghidoni, R., Cashman, J. R., Ceroni, M., and Cereda, C. (2010) SOD1 mRNA expression in sporadic amyotrophic lateral sclerosis. Neurobiol. Dis. 39, 198-203.
5. Rothstein, J. D. (2009) Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 65 (Suppl 1), S3-9.
6. Kerman, A., Liu, H. N., Croul, S., Bilbao, J., Rogaeva, E., Zinman, L., Robertson, J., and Chakrabartty, A. (2010) Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol. 119, 335-344.
7. Deng, H. X., Chen, W., Hong, S. T., Boycott, K. M., Gorrie, G. H., Siddique, N., Yang, Y., Fecto, F., Shi, Y., Zhai, H., Jiang, H., Hirano, M., Rampersaud, E., Jansen, G. H., Donkervoort, S., Bigio, E. H., Brooks, B. R., Ajroud, K., Sufit, R. L., Haines, J. L., Mugnaini, E., Pericak-Vance, M. A., and Siddique, T. (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211-215.
8. Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., Baralle, F., de Belleroche, J., Mitchell, J. D., Leigh, P. N., Al-Chalabi, A., Miller, C. C., Nicholson, G., and Shaw, C. E. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668-1672.
9. Chen-Plotkin, A. S., Lee, V. M., and Trojanowski, J. Q. (2010) TAR DNA-binding protein 43 in neurodegenerative disease. Nat. Rev. Neurol. 6, 211-220.
10. Kwiatkowski, T. J., Jr., Bosco, D. A., Leclerc, A. L., Tamrazian, E., Vanderburg, C. R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E. J., Munsat, T., Valdmanis, P., Rouleau, G. A., Hosler, B. A., Cortelli, P., de Jong, P. J., Yoshinaga, Y., Haines, J. L., Pericak-Vance, M. A., Yan, J., Ticozzi, N., Siddique, T., McKenna-Yasek, D., Sapp, P. C., Horvitz, H. R., Landers, J. E., and Brown, R. H., Jr. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205-1208.
11. Pokrishevsky, E., Grad, L. I., Yousefi, M., Wang, J., Mackenzie, I. R., and Cashman, N. R. (2012) Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PloS One 7, e35050.
12. Soto, C., and Estrada, L. D. (2008) Protein misfolding and neurodegeneration. Arch. Neurol. 65, 184-189.
13. Benmohamed, R., Arvanites, A. C., Kim, J., Ferrante, R. J., Silverman, R. B., Morimoto, R. I., and Kirsch, D. R. (2011) Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Scler. 12, 87-96.
14. Chen, T., Benmohamed, R., Kim, J., Smith, K., Amante, D., Morimoto, R. I., Kirsch, D. R., Ferrante, R. J., and Silverman, R. B. (2012) ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis. J. Med. Chem. 55, 515-527.
15. Chen, T., Benmohamed, R., Arvanites, A. C., Ralay Ranaivo, H., Morimoto, R. I., Ferrante, R. J., Watterson, D. M., Kirsch, D. R., and Silverman, R. B. (2011) Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis. Bioorg. Med. Chem. 19, 613-622.
16. Vermeiren, C., Hemptinne, I., Vanhoutte, N., Tilleux, S., Maloteaux, J. M., and Hermans, E. (2006) Loss of metabotropic glutamate receptor-mediated regulation of glutamate transport in chemically activated astrocytes in a rat model of amyotrophic lateral sclerosis. J. Neurochem 96, 719-731.
17. Matsumoto, G., Stojanovic, A., Holmberg, C. I., Kim, S., and Morimoto, R. I. (2005) Structural properties and neuronal toxicity of amyotrophic lateral sclerosis-associated Cu/Zn superoxide dismutase 1 aggregates. J. Cell Biol. 171, 75-85.
18. Morimoto, R. I. (2008) Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev. 22, 1427-1438.
19. Calamini, B., Silva, M. C., Madoux, F., Hutt, D. M., Khanna, S., Chalfant, M. A., Saldanha, S. A., Hodder, P., Tait, B. D., Garza, D., Balch, W. E., and Morimoto, R. I. (2012) Small-molecule proteostasis regulators for protein conformational diseases. Nat. Chem. Biol. 8, 185-196.
20. Trippier, P. C. (2013) Synthetic strategies for the biotinylation of bioactive small molecules. Chem Med Chem 8, 190-203.
21. Sato, S., Murata, A., Shirakawa, T., and Uesugi, M. (2010) Biochemical target isolation for novices: affinity-based strategies. Chem. Biol. 17, 616-623.
22. Trippier, P. C., Benmohammed, R., Kirsch, D. R., and Silverman, R. B. (2012) Substituted pyrazolones require N(2) hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1. Bioorg. Med. Chem. Lett. 22, 6647-6650.
23. Leslie, B. J., and Hergenrother, P. J. (2008) Identification of the cellular targets of bioactive small organic molecules using affinity reagents. Chem. Soc. Rev. 37, 1347-1360.
24. Sreenivasan, V. K., Kelf, T. A., Grebenik, E. A., Stremovskiy, O. A., Say, J. M., Rabeau, J. R., Zvyagin, A. V., and Deyev, S. M. (2013) A modular design of low-background bioassays based on a high-affinity molecular pair barstar:barnase. Proteomics 13, 1437-1443.
25. Switzer, R. C., 3rd, Merril, C. R., and Shifrin, S. (1979) A highly sensitive silver stain for detecting proteins and peptides in polyacrylamide gels. Anal. Biochem. 98, 231-237.
26. Aebersold, R., and Mann, M. (2003) Mass spectrometry-based proteomics. Nature 422, 198-207.
27. Kabashi, E., Agar, J. N., Taylor, D. M., Minotti, S., and Durham, H. D. (2004) Focal dysfunction of the proteasome: a pathogenic factor in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 89, 1325-1335.
28. Banks, G. T., and Fisher, E. M. (2008) Cytoplasmic dynein could be key to understanding neurodegeneration. Genome Biol. 9, 214.
29. Spiess, C., Meyer, A. S., Reissmann, S., and Frydman, J. (2004) Mechanism of the eukaryotic chaperonin: protein folding in the chamber of secrets. Trends Cell Biol. 14, 598-604.
30. Kitamura, A., Kubota, H., Pack, C. G., Matsumoto, G., Hirayama, S., Takahashi, Y., Kimura, H., Kinjo, M., Morimoto, R. I., and Nagata, K. (2006) Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat. Cell Biol. 8, 1163-1170.
31. Cheroni, C., Marino, M., Tortarolo, M., Veglianese, P., De Biasi, S., Fontana, E., Zuccarello, L. V., Maynard, C. J., Dantuma, N. P., and Bendotti, C. (2009) Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Hum. Mol. Genet. 18, 82-96.
32. Bar-Nun, S., and Glickman, M. H. (2012) Proteasomal AAAA-TPases: structure and function. Biochim. Biophys. Acta 1823, 67-82.
33. Guerrero, C., Milenkovic, T., Przulj, N., Kaiser, P., and Huang, L. (2008) Characterization of the proteasome interaction network using a QTAX-based tag-team strategy and protein interaction network analysis. Proc. Natl. Acad. Sci. U.S.A. 105, 13333-13338.
34. Valpuesta, J. M., Martin-Benito, J., Gomez-Puertas, P., Carrascosa, J. L., and Willison, K. R. (2002) Structure and function of a protein folding machine: the eukaryotic cytosolic chaperonin CCT. FEBS Lett. 529, 11-16.
35. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D. J. (1997) Gapped BLAST and PSIBLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402.
36. Huang, L., and Chen, C. H. (2009) Proteasome regulators: activators and inhibitors. Curr. Med. Chem. 16, 931-939.
37. Seo, H., Sonntag, K. C., Kim, W., Cattaneo, E., and Isacson, O. (2007) Proteasome activator enhances survival of Huntington' s disease neuronal model cells. PloS One 2, e238.
38. Lee, B. H., Lee, M. J., Park, S., Oh, D. C., Elsasser, S., Chen, P. C., Gartner, C., Dimova, N., Hanna, J., Gygi, S. P., Wilson, S. M., King, R. W., and Finley, D. (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179-184.